Nervio

Nervio operates at the intersection of digital health, medical devices, health diagnostics, and real-time clinical decision support. Its stated focus is narrower than general hospital AI: the company targets intraoperative neuromonitoring and the prevention of avoidable paralysis and severe neurologic complications during surgery. AIM™ is differentiated in the available profile by its autonomous neuromonitoring approach, which is intended to translate surgical data into immediate alerts and recommendations for clinicians. The company also combines software with a clinical and medical-device orientation, including expertise in intraoperative neurophysiology, neurosurgery, neurology, spinal surgery, FDA device evaluation, and complex drug-device launches. Two granted patents and additional patent publications support an identifiable intellectual-property base, while the US validation effort suggests a strategy focused on clinical credibility. Competitive positioning therefore appears specialized and technology-led, but remains difficult to benchmark quantitatively.

Nervio’s trajectory shows a progression from company formation in 2020 to a more focused clinical-validation and intellectual-property phase. The company raised $1 million in a seed round announced on Jan 1, 2020, followed by a $2.5 million seed round on Jan 1, 2023, bringing total recorded funding to $3.5 million. Patent activity spans Israel filings dated Jul 5, 2021, an international filing dated Jul 5, 2022, and two Jan 4, 2024 publications concerning neuromonitoring data analysis methods. These milestones indicate continued investment in the underlying data-processing and clinical workflow technology. Product development is represented by AIM™, an AI-powered intraoperative neuromonitoring system designed to generate real-time alerts and recommendations from raw surgical data. Hiring for software verification and validation, alongside US professional neurophysiologists, points to an inflection from core development toward quality assurance, clinical evidence, and market readiness. The growth story is therefore supported by funding, patents, product definition, and specialized hiring, but not yet by disclosed scale metrics.